Atlas market file · Equity · United States
Novartis AGNVS
- Last close
- 156.33
- Change
- +1.37%
- 96-bar range
- 142.25 – 160.57
- As of
- 7 Aug 2026
Novartis AG is a pharmaceutical preparations issuer listed as NVS on NYSE. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
NVS
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+31.86% over the window).
Source rail: Yahoo Finance chart API (NVS). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for NVS. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
Atlas Pro artifact
NVS Market Snapshot PDF
The latest snapshot audit passed. Atlas checks entitlement and evidence again when the PDF is requested.
Atlas Pro entitlement required. The release gate runs again when you request the file.
NVS public profile
Pharmaceutical preparations issuer. Novartis AG is connected to current market context, cited company sources and its retained research file.
Novartis AG trades as NVS on NYSE. Novartis AG (NVS) has a latest verified close of 156.33, up 1.37%, dated 7 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files NVS under USA Stocks for browsing.
What changed for Novartis AG today
Novartis AG (NVS) has delivered a solid performance in Q2, with sales growth driven by strong demand for Kesimpta and Scemblix. The company reaffirmed its full-year guidance, expecting low single-digit growth in net sales and a decline in core operating income. This comes as Novartis continues to advance its pipeline, with recent FDA approval for Fabhalta® (iptacopan) as the first complement inhibitor to slow kidney function decline in primary IgAN.
Novartis is a global leader in innovative medicines, with a strong commitment to patients and caregivers. The company’s technology platforms and product portfolio reflect its dedication to research and development, aiming to address unmet medical needs. However, the recent earnings report highlights the challenges of maintaining growth in a competitive market.
In Q2, Kesimpta generated USD 1.424 billion in sales, up 32% year-over-year, while Scemblix saw sales of USD 562 million, an 89% increase. Despite these strong performances, the company expects a decline in core operating income for the full year. The FDA approval of Fabhalta® (iptacopan) is a significant milestone, offering new hope for patients with primary IgAN.
For those looking to dive deeper into Novartis’ performance, the official product and news rail provides comprehensive insights into the company’s sales, pipeline advancements, and regulatory approvals. The chart and source context can be explored further at https://www.novartis.com/news/media-releases/novartis-delivered-sales-growth-q2-and-further-advanced-pipeline-full-year-guidance-reaffirmed.
While Novartis has made significant strides in Q2, the full-year guidance suggests a cautious outlook. The company’s ability to maintain growth amidst rising costs and competitive pressures will be a key factor to watch. also, the market uptake of Fabhalta® (iptacopan) will be crucial in determining its success.
Sources & evidence · 5 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
NVS technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on NVS
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep NVS research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
NVS FAQ
What is Novartis AG (NVS)?Novartis AG (NVS) has a latest verified close of 156.33, up 1.37%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
Novartis AG (NVS) has a latest verified close of 156.33, up 1.37%, dated 7 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for NVS?Novartis AG (NVS) has a latest verified close of 156.33, up 1.37%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the...
Novartis AG (NVS) has a latest verified close of 156.33, up 1.37%, dated 7 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files NVS under USA Stocks for browsing.
How often is the NVS page updated?The NVS public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The NVS public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for NVS?The NVS file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:NVS. SEC EDGAR provides the filing anchor for this issuer. The page separates verified...
The NVS file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:NVS. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on NVS?Yes. The workstation can open NVS, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open NVS, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this NVS page investment advice?No. The NVS page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The NVS page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →